BioCentury | Jan 12, 2021
Finance

Diverse syndicate stands behind EQRx’s mission with $500M series B round

...Arboretum Ventures participated in the series A round.EQRx Inc....
...– Programmed cell death 1 ligand 1 Lauren Martz EQRx Inc....
BioCentury | Oct 28, 2020
Deals

In third cancer deal, EQRx aims to bring down cost of PD-1, PD-L1 inhibitors

...deal with CStone, EQRx is looking to bring lower cost PD-1 and PD-L1 inhibitors to market.EQRx Inc. launched...
...death 1 ligand 1 PD-1 (PDCD1) (CD279) – Programmed cell death 1 Amanda Micklus CStone Pharmaceuticals Co. Ltd. EQRx Inc. Programmed...
BioCentury | Oct 8, 2020
Finance

Hillhouse’s Genor tops off busy year with IPO, plans to ‘transform’ pipeline

...to $40 million in development and sales milestones, plus royalties. Alexis Borisy’s high-profile U.S. start-up EQRx Inc....
BioCentury | Jul 23, 2020
Deals

EQRx brings in next-in-class CDK4/6, EGFR inhibitors in bid for radically cheaper drugs

...drugs to market in the next 10 years (see “Borisy Newco Disrupting Biopharma Model” ). EQRx Inc....
...upfront payment and developmental and regulatory milestones, plus commercial milestones and royalties. Karen Tkach Tuzman, Associate Editor EQRx Inc. G1...
BioCentury | Jun 17, 2020
Finance

Daily Chart: series A rounds holding steady

...see “Shiyu Backs Mabwell’s Massive Series A” ; “Megarounds for Chinese Biopharmas” ). The third, EQRx Inc....
BioCentury | May 30, 2020
Finance

GV’s 2020 viewpoint

...year continue the theme. In January, GV co-led a $200 million series A round for EQRx Inc....
...should have known each other all this time, but didn’t.” Karen Tkach Tuzman, Associate Editor GV Verve Therapeutics Inc. EQRx Inc. Rome...
BioCentury | Apr 28, 2020
Finance

Arch, Cormorant return to lead $200M megaround for Erasca

...as existing investors City Hill Ventures, Colt Ventures and LifeSci Venture Partners. The round matches EQRx Inc.’s...
BioCentury | Mar 10, 2020
Politics, Policy & Law

We’ve moved on from nude women parties. The progress is much bigger than that.

...luncheon, this year headlined by Sandra Horning, former Genentech Inc. CMO and now co-founder of EQRx Inc....
BioCentury | Feb 28, 2020
Finance

Verastem raises $100M, plots path forward with targeted cancer combo

...following the decision by former CEO Robert Forrester to step down. Forrester has since joined EQRx Inc....
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

...was nominated to the board of Moderna Inc. (NASDAQ:MRNA). Horning is also a co-founder of EQRx Inc....
Items per page:
1 - 10 of 11
BioCentury | Jan 12, 2021
Finance

Diverse syndicate stands behind EQRx’s mission with $500M series B round

...Arboretum Ventures participated in the series A round.EQRx Inc....
...– Programmed cell death 1 ligand 1 Lauren Martz EQRx Inc....
BioCentury | Oct 28, 2020
Deals

In third cancer deal, EQRx aims to bring down cost of PD-1, PD-L1 inhibitors

...deal with CStone, EQRx is looking to bring lower cost PD-1 and PD-L1 inhibitors to market.EQRx Inc. launched...
...death 1 ligand 1 PD-1 (PDCD1) (CD279) – Programmed cell death 1 Amanda Micklus CStone Pharmaceuticals Co. Ltd. EQRx Inc. Programmed...
BioCentury | Oct 8, 2020
Finance

Hillhouse’s Genor tops off busy year with IPO, plans to ‘transform’ pipeline

...to $40 million in development and sales milestones, plus royalties. Alexis Borisy’s high-profile U.S. start-up EQRx Inc....
BioCentury | Jul 23, 2020
Deals

EQRx brings in next-in-class CDK4/6, EGFR inhibitors in bid for radically cheaper drugs

...drugs to market in the next 10 years (see “Borisy Newco Disrupting Biopharma Model” ). EQRx Inc....
...upfront payment and developmental and regulatory milestones, plus commercial milestones and royalties. Karen Tkach Tuzman, Associate Editor EQRx Inc. G1...
BioCentury | Jun 17, 2020
Finance

Daily Chart: series A rounds holding steady

...see “Shiyu Backs Mabwell’s Massive Series A” ; “Megarounds for Chinese Biopharmas” ). The third, EQRx Inc....
BioCentury | May 30, 2020
Finance

GV’s 2020 viewpoint

...year continue the theme. In January, GV co-led a $200 million series A round for EQRx Inc....
...should have known each other all this time, but didn’t.” Karen Tkach Tuzman, Associate Editor GV Verve Therapeutics Inc. EQRx Inc. Rome...
BioCentury | Apr 28, 2020
Finance

Arch, Cormorant return to lead $200M megaround for Erasca

...as existing investors City Hill Ventures, Colt Ventures and LifeSci Venture Partners. The round matches EQRx Inc.’s...
BioCentury | Mar 10, 2020
Politics, Policy & Law

We’ve moved on from nude women parties. The progress is much bigger than that.

...luncheon, this year headlined by Sandra Horning, former Genentech Inc. CMO and now co-founder of EQRx Inc....
BioCentury | Feb 28, 2020
Finance

Verastem raises $100M, plots path forward with targeted cancer combo

...following the decision by former CEO Robert Forrester to step down. Forrester has since joined EQRx Inc....
BioCentury | Feb 6, 2020
Management Tracks

BioMarin CFO steps down; plus Atara, Epirium, Abalos, CytomX and more

...was nominated to the board of Moderna Inc. (NASDAQ:MRNA). Horning is also a co-founder of EQRx Inc....
Items per page:
1 - 10 of 11